OPK Opko Health Inc.

2.07
+0.03  (+1%)
Previous Close 2.04
Open 2.04
Price To Book 0.74
Market Cap 1,274,294,163
Shares 615,601,045
Volume 1,920,599
Short Ratio
Av. Daily Volume 3,410,166
Stock charts supplied by TradingView

NewsSee all news

  1. OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement

    Veeva CRM empowers pharmaceutical field representatives with the right information they need to deliver a personalized customer experience Veeva Systems (NYSE:VEEV) today announced that OPKO Health (NASDAQ:OPK), a

  2. OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

    MIAMI, Aug. 29, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the last patient has completed the final visit in the Company's pivotal Phase 3 study evaluating the safety and efficacy of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 initial open label data due 4Q 2019.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data due 4Q 2019.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement

    Veeva CRM empowers pharmaceutical field representatives with the right information they need to deliver a personalized customer experience Veeva Systems (NYSE:VEEV) today announced that OPKO Health (NASDAQ:OPK), a

  2. OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

    MIAMI, Aug. 29, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the last patient has completed the final visit in the Company's pivotal Phase 3 study evaluating the safety and efficacy of